Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues

• Published in: Surgical oncology Vol. 3; no. 4; p. 237
• Main Authors: Robertson, C N, Roberson, K M, Herzberg, A J, Kerns, B J, Dodge, R K, Paulson, D F
• Format: Journal Article
• Language: English
• Published: Netherlands 01-08-1994
• Subjects: Aged; Humans; Immunohistochemistry; Male; Middle Aged; Precancerous Conditions - metabolism; Precancerous Conditions - pathology; Prostatic Hyperplasia - metabolism; Prostatic Hyperplasia - pathology; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Receptor, Epidermal Growth Factor - analysis; Receptor, Epidermal Growth Factor - biosynthesis; Transforming Growth Factor alpha - analysis; Transforming Growth Factor alpha - biosynthesis
• ISSN: 0960-7404
• DOI: 10.1016/0960-7404(94)90039-6

Immunohistochemical examination of radical prostatectomy specimens from 57 patients was performed to determine the differential expression of transforming growth factor alpha in the human prostate. In addition, epidermal growth factor receptor (EGFr) immunoreactivity was assessed in each case. Stromal versus epithelial staining was determined for each histological subtype: benign prostatic hypertrophy (BPH), prostatic intra-epithelial neoplasia (PIN), and prostatic cancer (CaP) by a single pathologist reviewer. TGFa staining was predominant in stroma while EGFr was localized to the epithelial basal cell layer. Immunoreactivity of both TGFa (P = 0.002) and EGFr (P < 0.001) revealed a significant reduction in CaP compared to BPH or PIN. Autocrine stimulation of EGFr by TGFa or other unrecognized factors may be present in CaP. Conversely, altered stromal influence of CaP via TGFa may be present. These observations could form the basis for future cancer therapeutic strategies using antagonist factors.